Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations

被引：16
作者：
Wang, Yang [1 ]
Li, Jingxin [2 ]
Wang, Yuxiao [1 ]
Gu, Wei [3 ]
Zhu, Fengcai [1 ,2 ]
机构：
[1] Southeast Univ, Sch Publ Hlth, Nanjing, Jiangsu, Peoples R China
[2] Jiangsu Prov Ctr Dis Control & Prevent, Nanjing, Jiangsu, Peoples R China
[3] Nanjing Med Univ, Sch Publ Hlth, Nanjing, Jiangsu, Peoples R China
来源：
HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2018年 / 14卷 / 04期
关键词：
clinical trials; high-risk population; immunization strategy; pneumococcal polysaccharide vaccine; vaccine efficacy; CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE MYOCARDIAL-INFARCTION; WORKING-AGE ADULTS; CONJUGATE VACCINE; STREPTOCOCCUS-PNEUMONIAE; MATERNAL IMMUNIZATION; ADVISORY-COMMITTEE; COST-EFFECTIVENESS; CLINICAL EFFECTIVENESS; DISEASE EPIDEMIOLOGY;
D O I：
10.1080/21645515.2017.1409316
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Streptococcus pneumonia (S. pneumoniae) is responsible for significant morbidity and mortality throughout the world. The 23-valent pneumococcal polysaccharide vaccines (PPV23) have been widely used for many years, but challenges are remaining in some respects, especially for its effectiveness among high-risk populations and older adults. This review aims to summarize recent clinical trials and studies of PPV23 vaccination among healthy people >= 2 years of age and those with high-risk conditions such as pregnant women, individuals with immunocompromising diseases and other chronic conditions, and provide health officials in China and other developing countries a comprehensive understanding of the current vaccination strategies for PPV23 and for the combined use of PPV23 and pneumococcal conjugate vaccines (PCVs) in adults.
引用
收藏
页码：1003 / 1012
页数：10
相关论文
共 50 条
  • [31] Recommendations for the use of the 23-valent polysaccharide pneumococcal vaccine in adults: A Belgian consensus report
    Peetermans, WE
    Van de Vyver, N
    Van Laethem, Y
    Van Damme, P
    Thiry, N
    Trefois, P
    Geerts, P
    Schetgen, M
    Peleman, R
    Swennen, B
    Verhaegen, J
    ACTA CLINICA BELGICA, 2005, 60 (06) : 329 - 337
  • [32] Evaluation of effectiveness, safety and cost-benefit of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-Infected patients
    Zou, Xiaobai
    He, Jianmei
    Zheng, Jun
    Liang, Mengran
    Gao, Jinjin
    Huang, Jianwen
    Jiang, Yang
    Jiang, Yonglin
    Chen, Xi
    VACCINE, 2022, 40 (01) : 37 - 42
  • [33] Failure to vaccinate or failure of vaccine? Effectiveness of the 23-valent pneumococcal polysaccharide vaccine program in Indigenous adults in the Northern Territory of Australia
    Moberley, S.
    Krause, V.
    Cook, H.
    Mulholland, K.
    Carapetis, J.
    Torzillo, P.
    Andrews, R.
    VACCINE, 2010, 28 (11) : 2296 - 2301
  • [34] Revaccination of adults with spinal cord injury using the 23-valent pneumococcal polysaccharide vaccine
    Waites, Ken B.
    Canupp, Kay C.
    Chen, Yu-ying
    DeVivo, Michael J.
    Nahm, Moon H.
    JOURNAL OF SPINAL CORD MEDICINE, 2008, 31 (01) : 53 - 59
  • [35] Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-infected pregnant women and kinetics of passively acquired antibodies in young infants
    Almeida, Volia De Carvalho
    Mussi-Pinhata, Marisa Marcia
    Sandoval De Souza, Cleonice Barbosa
    Kubo, Christina Arslanian
    Martinez, Edson Zangiacomi
    Carneiro-Sampaio, Magda Maria
    Duarte, Geraldo
    VACCINE, 2009, 27 (29) : 3856 - 3861
  • [36] Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia
    Chen, C.
    Beutels, P.
    Wood, J.
    Menzies, R.
    Maclntyre, C. R.
    McIntyre, P.
    Newall, A. T.
    VACCINE, 2018, 36 (42) : 6307 - 6313
  • [37] A case series evaluating the serological response of adult asthma patients to the 23-valent pneumococcal polysaccharide vaccine
    Laratta, C. R.
    Williams, K.
    Vethanayagam, D.
    Ulanova, M.
    Vliagoftis, H.
    ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY, 2017, 13
  • [38] Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: A matched case-control study
    Vila-Corcoles, Angel
    Salsench, Elisabet
    Rodriguez-Blanco, Teresa
    Ochoa-Gondar, Olga
    de Diego, Cinta
    Valdivieso, Amparo
    Hospital, Imma
    Gomez-Bertomeu, Frederic
    Raga, Xavier
    VACCINE, 2009, 27 (10) : 1504 - 1510
  • [39] Safety of varying dosages of 7-valent pneumococcal protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
    Jackson, LA
    Neuzil, KM
    Whitney, CG
    Starkovich, P
    Dunstan, M
    Yu, OC
    Nelson, JC
    Feikin, DR
    Shay, DK
    Baggs, J
    Carste, B
    Nahm, MH
    Carlone, G
    VACCINE, 2005, 23 (28) : 3697 - 3703
  • [40] Cost-Effectiveness Analysis of 23-Valent Pneumococcal Polysaccharide Vaccine Program for the Elderly Aged 60 Years or Older in Shanghai, China
    Sun, Xiaodong
    Tang, Yuekun
    Ma, Xiaoying
    Guo, Xiang
    Huang, Zhuoying
    Ren, Jia
    Qiu, Jing
    Jiang, Hongli
    Lu, Yihan
    FRONTIERS IN PUBLIC HEALTH, 2021, 9
12345